What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 13 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. The company has an average price target of $109.54 with a high of $140.00 and a low of $69.00. The average price target has increased by 1.24% over the past month.
July 03, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical has received mixed reviews from analysts, with an average price target of $109.54. The average price target has increased by 1.24% over the past month.
The mixed reviews from analysts indicate uncertainty about the future performance of the stock. However, the increase in the average price target over the past month suggests a slightly positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100